Novo Nordisk seeks extended approval for diabetes drug in the US

The US FDA will now decide whether to expand the label for Novo Nordisk's drug Ozempic to also include a higher dose of the drug.
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Danish pharmaceutical firm Novo Nordisk has submitted a label expansion application for its diabetes drug Ozempic to the US Food and Drug Administration (FDA), according to a company press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading